Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGON NASDAQ:COGT NASDAQ:LNTH NASDAQ:QURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$69.54-6.0%$66.95$23.38▼$75.50$6.53B0.41899,480 shs1.25 million shsCOGTCogent Biosciences$34.19-0.3%$35.90$4.55▼$43.73$5.86B0.371.54 million shs1.25 million shsLNTHLantheus$96.67+0.2%$81.60$47.25▼$98.27$6.28B-0.08900,019 shs843,451 shsQUREuniQure$27.75-4.9%$17.95$8.73▼$71.50$1.84B0.872.15 million shs1.51 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology-6.03%+0.52%+3.36%+35.03%+187.71%COGTCogent Biosciences-0.29%-1.72%-6.30%-6.41%+600.61%LNTHLantheus+0.22%+6.23%+16.84%+39.33%+22.66%QUREuniQure-4.87%+14.91%+62.38%+35.37%+119.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$69.54-6.0%$66.95$23.38▼$75.50$6.53B0.41899,480 shs1.25 million shsCOGTCogent Biosciences$34.19-0.3%$35.90$4.55▼$43.73$5.86B0.371.54 million shs1.25 million shsLNTHLantheus$96.67+0.2%$81.60$47.25▼$98.27$6.28B-0.08900,019 shs843,451 shsQUREuniQure$27.75-4.9%$17.95$8.73▼$71.50$1.84B0.872.15 million shs1.51 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology-6.03%+0.52%+3.36%+35.03%+187.71%COGTCogent Biosciences-0.29%-1.72%-6.30%-6.41%+600.61%LNTHLantheus+0.22%+6.23%+16.84%+39.33%+22.66%QUREuniQure-4.87%+14.91%+62.38%+35.37%+119.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGONCG Oncology 2.77Moderate Buy$81.7317.53% UpsideCOGTCogent Biosciences 2.86Moderate Buy$43.7327.89% UpsideLNTHLantheus 2.73Moderate Buy$99.713.15% UpsideQUREuniQure 2.53Moderate Buy$42.8354.35% UpsideCurrent Analyst Ratings BreakdownLatest QURE, CGON, COGT, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026CGONCG Oncology Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$77.00 ➝ $82.005/11/2026CGONCG Oncology JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$91.00 ➝ $96.005/11/2026CGONCG Oncology Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$79.00 ➝ $81.005/11/2026CGONCG Oncology Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.00 ➝ $77.005/11/2026CGONCG Oncology WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$77.00 ➝ $80.005/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.005/8/2026LNTHLantheus CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/8/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$85.00 ➝ $115.005/8/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$95.00 ➝ $100.005/7/2026LNTHLantheus The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$94.005/6/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $50.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGONCG Oncology$4.04M1,518.18N/AN/A$12.38 per share5.62COGTCogent BiosciencesN/AN/AN/AN/A$3.18 per shareN/ALNTHLantheus$1.54B4.08$6.40 per share15.11$18.62 per share5.19QUREuniQure$16.10M108.71N/AN/A$2.37 per share11.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGONCG Oncology-$160.99M-$2.33N/AN/AN/AN/A-23.33%-22.24%N/ACOGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%N/ALNTHLantheus$233.56M$4.1523.2917.94N/A18.05%29.32%15.00%N/AQUREuniQure-$198.97M-$3.48N/AN/AN/A-1,154.42%-145.81%-27.15%N/ALatest QURE, CGON, COGT, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026CGONCG Oncology-$0.58-$0.71-$0.13-$0.71$0.45 million$1.08 million5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/A5/5/2026Q1 2026QUREuniQure-$0.88-$0.85+$0.03-$0.85$5.21 million$3.56 million3/3/2026Q4 2025QUREuniQure-$0.93-$0.56+$0.37-$0.56$4.84 million$5.57 million2/27/2026Q4 2025CGONCG Oncology-$0.61-$0.51+$0.10-$0.51N/A$2.32 million2/26/2026Q4 2025LNTHLantheus$1.17$1.67+$0.50$0.82$367.03 million$406.79 million2/17/2026Q4 2025COGTCogent Biosciences-$0.51-$0.55-$0.04-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGONCG OncologyN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGONCG OncologyN/A31.3024.58COGTCogent Biosciences0.4115.1415.14LNTHLantheus0.472.832.64QUREuniQure0.3310.4010.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGONCG Oncology26.56%COGTCogent BiosciencesN/ALNTHLantheus99.06%QUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipCGONCG Oncology4.80%COGTCogent Biosciences7.29%LNTHLantheus1.70%QUREuniQure4.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGONCG Oncology6188.20 million83.97 millionOptionableCOGTCogent Biosciences80170.87 million158.41 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableQUREuniQure50063.07 million60.05 millionOptionableQURE, CGON, COGT, and LNTH HeadlinesRecent News About These CompaniesuniQure (NASDAQ:QURE) Insider Walid Abi-Saab Sells 45,000 SharesMay 13 at 6:11 AM | insidertrades.comUniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In PlayMay 12 at 10:24 AM | seekingalpha.comNan Fung Trinity HK Ltd. Purchases New Holdings in uniQure N.V. $QUREMay 10, 2026 | marketbeat.comuniQure N.V. (NASDAQ:QURE) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMay 8, 2026 | finance.yahoo.comHC Wainwright Issues Optimistic Outlook for uniQure EarningsMay 8, 2026 | marketbeat.comFDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?May 7, 2026 | fiercepharma.comFWhat is HC Wainwright's Forecast for uniQure Q1 Earnings?May 7, 2026 | marketbeat.comUniQure plans UK AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029May 7, 2026 | msn.comUniQure plans U.K. AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029May 5, 2026 | seekingalpha.comuniQure Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comuniQure N.V. (QURE) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comuniQure (NASDAQ:QURE) Issues Quarterly Earnings ResultsMay 5, 2026 | marketbeat.comuniQure (QURE) Reports Q1 Loss, Misses Revenue EstimatesMay 5, 2026 | zacks.comUniQure: Q1 Earnings SnapshotMay 5, 2026 | chron.comuniQure Announces First Quarter 2026 Financial Results and Provides Recent Company UpdatesMay 5, 2026 | globenewswire.comHow The uniQure (QURE) Investment Story Is Shifting With AMT-130 And Regulatory UncertaintyMay 4, 2026 | finance.yahoo.comuniQure (NASDAQ:QURE) Shares Up 6.3% - Still a Buy?May 4, 2026 | marketbeat.comuniQure N.V. (NASDAQ:QURE) Receives $42.83 Consensus Price Target from AnalystsMay 4, 2026 | americanbankingnews.comuniQure’s AMT-130 Regulatory Progress Sharpens Huntington’s Disease Investment CaseMay 3, 2026 | finance.yahoo.comJennison Associates LLC Boosts Stake in uniQure N.V. $QUREMay 2, 2026 | marketbeat.comuniQure (QURE) Projected to Post Earnings on TuesdayMay 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQURE, CGON, COGT, and LNTH Company DescriptionsCG Oncology NASDAQ:CGON$69.54 -4.46 (-6.03%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$69.54 0.00 (0.00%) As of 06:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Cogent Biosciences NASDAQ:COGT$34.19 -0.10 (-0.29%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$34.34 +0.15 (+0.45%) As of 06:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Lantheus NASDAQ:LNTH$96.67 +0.21 (+0.22%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$96.72 +0.05 (+0.05%) As of 06:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.uniQure NASDAQ:QURE$27.75 -1.42 (-4.87%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$27.14 -0.61 (-2.22%) As of 06:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
